lapatinib has been researched along with buspirone in 7 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (buspirone) | Trials (buspirone) | Recent Studies (post-2010) (buspirone) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 2,096 | 351 | 382 |
| Protein | Taxonomy | lapatinib (IC50) | buspirone (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.025 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 1.75 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.024 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.323 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 2.125 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
| D | Rattus norvegicus (Norway rat) | 0.12 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0266 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 4 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.077 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.286 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.016 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.12 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 2.125 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.044 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.75 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 4.16 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.2055 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.9811 | |
| Alpha-2A adrenergic receptor | Bos taurus (cattle) | 0.025 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.7 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.2666 | |
| Lysosomal alpha-glucosidase | Bos taurus (cattle) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
2 review(s) available for lapatinib and buspirone
| Article | Year |
|---|---|
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for lapatinib and buspirone
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |